Pharmacovigilance Market Size By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-house, Contract Outsourcing) Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Spain, Italy, France, China, Japan, India, Australia, Argentina, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Qatar, Israel), Application Potential, Competitive Market Share & Forecast, 2018 - 2024

Pharmacovigilance Market will exceed USD 8.0 billion by 2024; as per a new research report.

Rising incidences of adverse drug reactions (ADRs) leading to increase in morbidity and mortality rates across the globe is primary driver for pharmacovigilance market growth. Approximately 5% of the total hospitalizations every year are due to adverse drug reactions creating a huge healthcare burden across the globe. Such factors lead to increase in demand for monitoring drug safety and efficacy thereby augmenting pharmacovigilance industry growth. 

Upsurge in drug development by pharmaceutical companies owing to increasing chronic diseases worldwide is another major factor contributing towards market growth. In addition, regulatory authorities such as European Medicines Agency and U.S. FDA have intensified drug safety mandates prior and post commercialization of drugs further boosting industry size.

Rising trend of outsourcing pharmacovigilance services to contract research organizations in developing countries will further favor pharmacovigilance industry expansion. However, data security risks along with dearth of skilled healthcare personnel will hinder market growth over the forecast timeline. 

Pharmacovigilance phase IV clinical trial business segment market was USD 2.9 billion in 2017 owing to increasing drug safety concerns and growing public health awareness about adverse drug events. It aims at continuous safety surveillance through adverse event monitoring till the drug is marketed.

In-house pharmacovigilance business segment was valued at USD 1.7 billion in 2017 and is expected to show considerable growth by 2024. Issues pertaining to data confidentiality, data safety, accountability and commitment associated with outsourcing services are some of the prime factors favoring companies to opt for in-house pharmacovigilance. 

U.S. pharmacovigilance market was valued over USD 1.2 billion in 2017. Rising death rates due to adverse drug reactions and growing patient concerns relating to safety and efficacy of drugs in the country are prominent factors for business growth. Increasing funding for clinical trials along with presence of well-established industry players in the U.S. will further drive U.S. pharmacovigilance market.

Italy pharmacovigilance market is projected to grow at a rapid 10.6% CAGR from 2018 to 2024 due to presence of favorable regulatory authorities in the country. The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) regulates the national pharmacovigilance system in association with the rules laid down at EU level by the EMA. The organization is responsible for improving pharmacovigilance knowledge and increase the number of ADR reports up to the gold standard level established by the WHO. Such factors will drive regional growth in the coming years.

Increasing outsourcing of clinical trials to developing countries such as India and China due to low operating costs coupled with availability of large diverse patient pool for conducting clinical trials in these countries will foster Asia Pacific pharmacovigilance market growth.

Few notable industry players are IQVIA (QuintilesIMS), InVentiv Health Clinical, LabCorp, PAREXEL, Accenture, Cognizant, and TCS. Strategic collaborations, mergers and acquisitions, and providing customized services are key sustainability strategies adopted by these industry players.
Report Content
 
 Chapter 1.  Methodology
 
 1.1. Methodology
 
 1.2. Market definitions
 
 1.3. Forecast parameters
 
 1.4. Data sources
 
 1.4.1.  Secondary
 
 1.4.1.1. Paid sources
 
 1.4.1.2. Unpaid sources
 
 1.4.2.  Primary
 
 Chapter 2.  Executive Summary
 
 2.1. Pharmacovigilance industry 360 degree synopsis, 2013 - 2024 (USD Million)
 
 2.1.1.  Business trends
 
 2.1.2.  Clinical trial phase trends
 
 2.1.3.  Service provider trends
 
 2.1.4.  Regional trends
 
 Chapter 3.  Pharmacovigilance Industry Insights
 
 3.1. Industry segmentation
 
 3.2. Industry landscape, 2013 - 2024
 
 3.3. Industry impact forces
 
 3.3.1.  Growth drivers
 
 3.3.1.1.    Increase in adoption rate of outsourcing services in Asia Pacific
 
 3.3.1.2.    Increasing consumption of drugs in developed regions
 
 3.3.1.3.    Rise in adverse drug reactions (ADR) and drug toxicity
 
 3.3.1.4.    Increasing acceptance of personalized medicine in developed regions  
 
 3.3.1.5.    Effective global harmonization practices
 
 3.3.2.  Industry pitfalls and challenges
 
 3.3.2.1.    Dearth of skilled personnel
 
 3.3.2.2.    High risk associated with data security
 
 3.4. Growth potential analysis
 
 3.4.1.  By clinical trial phase
 
 3.4.2.  By service provider
 
 3.5. New business models
 
 3.6. Porter's analysis
 
 3.7. Regulatory landscape
 
 3.8. Pharmacovigilance reporting system
 
 3.9. Competitive landscape
 
 3.9.1.  Company market share analysis, 2017
 
 3.9.2.  Strategy dashboard
 
 3.10. Pharmacovigilance service landscape
 
 3.11. PESTEL analysis
 
 Chapter 4.  Pharmacovigilance Market, By Clinical Trial Phase
 
 4.1. Key segment trends
 
 4.2. Preclinical
 
 4.2.1.  Market size, by region, 2013-2024 (USD Million)
 
 4.3. Phase I
 
 4.3.1.  Market size, by region, 2013-2024 (USD Million)
 
 4.4. Phase II
 
 4.4.1.  Market size, by region, 2013-2024 (USD Million)
 
 4.5. Phase III
 
 4.5.1.  Market size, by region, 2013-2024 (USD Million)
 
 4.6. Phase IV
 
 4.6.1.  Market size, by region, 2013-2024 (USD Million)
 
 Chapter 5.  Pharmacovigilance Market, By Service Provider
 
 5.1. Key segment trends
 
 5.2. In-house
 
 5.2.1.  Market size, by region, 2013-2024 (USD Million)
 
 5.3. Contract outsourcing
 
 5.3.1.  Market size, by region, 2013-2024 (USD Million)
 
 Chapter 6.  Pharmacovigilance Market, By Region
 
 6.1. Key regional trends
 
 6.2. North America
 
 6.2.1. Market size, by country, 2013 - 2024 (USD Million)
 
 6.2.2.  Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.2.3.  Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.2.4.  U.S.
 
 6.2.4.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.2.4.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.2.4.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.2.5. Canada
 
 6.2.5.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.2.5.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.2.5.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.3. Europe
 
 6.3.1. Market size, by country, 2013 - 2024 (USD Million)
 
 6.3.2.  Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.3.3.  Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.3.4.  Germany
 
 6.3.4.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.3.4.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.3.4.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.3.5. UK
 
 6.3.5.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.3.5.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.3.5.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.3.6. Spain
 
 6.3.6.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.3.6.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.3.6.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.3.7. Italy
 
 6.3.7.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.3.7.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.3.7.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.3.8. France
 
 6.3.8.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.3.8.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.3.8.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.4. Asia Pacific
 
 6.4.1. Market size, by country, 2013 - 2024 (USD Million)
 
 6.4.2.  Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.4.3.  Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.4.4.  Japan
 
 6.4.4.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.4.4.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.4.4.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.4.5. China
 
 6.4.5.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.4.5.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.4.5.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.4.6. India
 
 6.4.6.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.4.6.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.4.6.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.4.7. Australia
 
 6.4.7.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.4.7.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.4.7.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.5. Latin America
 
 6.5.1. Market size, by country, 2013 - 2024 (USD Million)
 
 6.5.2.  Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.5.3.  Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.5.4.  Argentina
 
 6.5.4.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.5.4.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.5.4.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.5.5. Brazil
 
 6.5.5.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.5.5.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.5.5.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.5.6. Mexico
 
 6.5.6.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.5.6.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.5.6.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.6. MEA
 
 6.6.1. Market size, by country, 2013 - 2024 (USD Million)
 
 6.6.2.  Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.6.3.  Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.6.4.  South Africa
 
 6.6.4.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.6.4.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.6.4.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.6.5.  UAE
 
 6.6.5.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.6.5.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.6.5.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.6.6.  Saudi Arabia
 
 6.6.6.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.6.6.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.6.6.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.6.7.  Qatar
 
 6.6.7.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.6.7.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.6.7.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 6.6.8.  Israel
 
 6.6.8.1.    Market size, by country, 2013 - 2024 (USD Million)
 
 6.6.8.2.    Market size, by clinical trial phase, 2013 - 2024 (USD Million)
 
 6.6.8.3.    Market size, by service provider, 2013 - 2024 (USD Million)
 
 Chapter 7.  Company Profiles
 
 7.1. Accenture
 
 7.1.1.   Business overview
 
 7.1.2.  Financial data
 
 7.1.3.  Product landscape
 
 7.1.4.  Strategic outlook
 
 7.1.5.  SWOT analysis
 
 7.2. Boehringer Ingelheim
 
 7.2.1.   Business overview
 
 7.2.2.  Financial data
 
 7.2.3.  Product landscape
 
 7.2.4.  Strategic outlook
 
 7.2.5.  SWOT analysis
 
 7.3. Bristol-Myers Squibb
 
 7.3.1.   Business overview
 
 7.3.2.  Financial data
 
 7.3.3.  Product landscape
 
 7.3.4.  Strategic outlook
 
 7.3.5.  SWOT analysis
 
 7.4. Clinquest Group B.V.
 
 7.4.1.   Business overview
 
 7.4.2.  Financial data
 
 7.4.3.  Product landscape
 
 7.4.4.  Strategic outlook
 
 7.4.5.  SWOT analysis
 
 7.5. Cognizant Technology Solutions Corporation
 
 7.5.1.   Business overview
 
 7.5.2.  Financial data
 
 7.5.3.  Product landscape
 
 7.5.4.  Strategic outlook
 
 7.5.5.  SWOT analysis
 
 7.6. Ecron Acunova Ltd.
 
 7.6.1.   Business overview
 
 7.6.2.  Financial data
 
 7.6.3.  Product landscape
 
 7.6.4.  Strategic outlook
 
 7.6.5.  SWOT analysis
 
 7.7. F. Hoffmann-La Roche Ltd.
 
 7.7.1.   Business overview
 
 7.7.2.  Financial data
 
 7.7.3.  Product landscape
 
 7.7.4.  Strategic outlook
 
 7.7.5.  SWOT analysis
 
 7.8. Foresight Group International AG
 
 7.8.1.   Business overview
 
 7.8.2.  Financial data
 
 7.8.3.  Product landscape
 
 7.8.4.  Strategic outlook
 
 7.8.5.  SWOT analysis
 
 7.9. GlaxoSmithKline Plc
 
 7.9.1.   Business overview
 
 7.9.2.  Financial data
 
 7.9.3.  Product landscape
 
 7.9.4.  Strategic outlook
 
 7.9.5.  SWOT analysis
 
 7.10. HCL Technologies
 
 7.10.1.    Business overview
 
 7.10.2.  Financial data
 
 7.10.3.  Product landscape
 
 7.10.4.  Strategic outlook
 
 7.10.5.  SWOT analysis
 
 7.11. IBM Corporation
 
 7.11.1.    Business overview
 
 7.11.2.  Financial data
 
 7.11.3.  Product landscape
 
 7.11.4.  Strategic outlook
 
 7.11.5.  SWOT analysis
 
 7.12. ICON plc
 
 7.12.1.    Business overview
 
 7.12.2.  Financial data
 
 7.12.3.  Product landscape
 
 7.12.4.  Strategic outlook
 
 7.12.5.  SWOT analysis
 
 7.13. iGATE Corporation (Capgemini)
 
 7.13.1.    Business overview
 
 7.13.2.  Financial data
 
 7.13.3.  Product landscape
 
 7.13.4.  Strategic outlook
 
 7.13.5.  SWOT analysis
 
 7.14. Infosys Ltd.
 
 7.14.1.    Business overview
 
 7.14.2.  Financial data
 
 7.14.3.  Product landscape
 
 7.14.4.  Strategic outlook
 
 7.14.5.  SWOT analysis
 
 7.15. InVentiv Health Clinical
 
 7.15.1.    Business overview
 
 7.15.2.  Financial data
 
 7.15.3.  Product landscape
 
 7.15.4.  Strategic outlook
 
 7.15.5.  SWOT analysis
 
 7.16. Ipca Laboratories Ltd.
 
 7.16.1.    Business overview
 
 7.16.2.  Financial data
 
 7.16.3.  Product landscape
 
 7.16.4.  Strategic outlook
 
 7.16.5.  SWOT analysis
 
 7.17. IQVIA (QuintilesIMS)
 
 7.17.1.    Business overview
 
 7.17.2.  Financial data
 
 7.17.3.  Product landscape
 
 7.17.4.  Strategic outlook
 
 7.17.5.  SWOT analysis
 
 7.18. ITclinical
 
 7.18.1.    Business overview
 
 7.18.2.  Financial data
 
 7.18.3.  Product landscape
 
 7.18.4.  Strategic outlook
 
 7.18.5.  SWOT analysis
 
 7.19. Janssen Research & Development, LLC
 
 7.19.1.    Business overview
 
 7.19.2.  Financial data
 
 7.19.3.  Product landscape
 
 7.19.4.  Strategic outlook
 
 7.19.5.  SWOT analysis
 
 7.20. Laboratory Corporation of America Holdings
 
 7.20.1.    Business overview
 
 7.20.2.  Financial data
 
 7.20.3.  Product landscape
 
 7.20.4.  Strategic outlook
 
 7.20.5.  SWOT analysis
 
 7.21. Novartis AG
 
 7.21.1.    Business overview
 
 7.21.2.  Financial data
 
 7.21.3.  Product landscape
 
 7.21.4.  Strategic outlook
 
 7.21.5.  SWOT analysis
 
 7.22. Oracle Corporation
 
 7.22.1.    Business overview
 
 7.22.2.  Financial data
 
 7.22.3.  Product landscape
 
 7.22.4.  Strategic outlook
 
 7.22.5.  SWOT analysis
 
 7.23. PAREXEL International Corporation
 
 7.23.1.    Business overview
 
 7.23.2.  Financial data
 
 7.23.3.  Product landscape
 
 7.23.4.  Strategic outlook
 
 7.23.5.  SWOT analysis
 
 7.24. Pfizer
 
 7.24.1.    Business overview
 
 7.24.2.  Financial data
 
 7.24.3.  Product landscape
 
 7.24.4.  Strategic outlook
 
 7.24.5.  SWOT analysis
 
 7.25. Sanofi Aventis
 
 7.25.1.    Business overview
 
 7.25.2.  Financial data
 
 7.25.3.  Product landscape
 
 7.25.4.  Strategic outlook
 
 7.25.5.  SWOT analysis
 
 7.26. TCS
 
 7.26.1.    Business overview
 
 7.26.2.  Financial data
 
 7.26.3.  Product landscape
 
 7.26.4.  Strategic outlook
 
 7.26.5.  SWOT analysis
 
 7.27. Telerx (C3i Solutions)
 
 7.27.1.    Business overview
 
 7.27.2.  Financial data
 
 7.27.3.  Product landscape
 
 7.27.4.  Strategic outlook
 
 7.27.5.  SWOT analysis
 
 7.28. Wipro
 
 7.28.1.    Business overview
 
 7.28.2.  Financial data
 
 7.28.3.  Product landscape
 
 7.28.4.  Strategic outlook
 
 7.28.5.  SWOT analysis

Data Tables TABLE 1. Pharmacovigilance industry 360 0 synopsis, 2013 - 2024 TABLE 2. Global pharmacovigilance market, 2013 - 2024 (USD Million) TABLE 3. Global pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 4. Global pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 5. Global pharmacovigilance market, by region, 2013 - 2024 (USD Million) TABLE 6. Industry impact forces TABLE 7. Pharmacovigilance regulatory initiatives TABLE 8. Preclinical market size, by region, 2013 - 2024 (USD Million) TABLE 9. Phase I market size, by region, 2013 - 2024 (USD Million) TABLE 10. Phase II market size, by region, 2013 - 2024 (USD Million) TABLE 11. Phase III market size, by region, 2013 - 2024 (USD Million) TABLE 12. Phase IV market size, by region, 2013 - 2024 (USD Million) TABLE 13. In-House market size, by region, 2013 - 2024 (USD Million) TABLE 14. Contract outsourcing market size, by region, 2013 - 2024 (USD Million) TABLE 15. North America pharmacovigilance market, by country, 2013 - 2024 (USD Million) TABLE 16. North America pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 17. North America pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 18. U.S. pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 19. U.S. pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 20. Canada pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 21. Canada pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 22. Europe pharmacovigilance market, by country, 2013 - 2024 (USD Million) TABLE 23. Europe pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 24. Europe pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 25. Germany pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 26. Germany pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 27. UK pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 28. UK pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 29. Spain pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 30. Spain pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 31. Italy pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 32. Italy pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 33. France pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 34. France pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 35. Asia Pacific pharmacovigilance market, by country, 2013 - 2024 (USD Million) TABLE 36. Asia Pacific pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 37. Asia Pacific pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 38. Japan pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 39. Japan pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 40. China pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 41. China pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 42. India pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 43. India pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 44. Australia pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 45. Australia pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 46. Latin America pharmacovigilance market, by country, 2013 - 2024 (USD Million) TABLE 47. Latin America pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 48. Latin America pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 49. Argentina pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 50. Argentina pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 51. Brazil pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 52. Brazil pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 53. Mexico pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 54. Mexico pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 55. MEA pharmacovigilance market, by country, 2013 - 2024 (USD Million) TABLE 56. MEA pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 57. MEA pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 58. South Africa pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 59. South Africa pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 60. UAE pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 61. UAE pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 62. Saudi Arabia pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 63. Saudi Arabia pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 64. Qatar pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 65. Qatar pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) TABLE 66. Israel pharmacovigilance market, by clinical trial phase, 2013 - 2024 (USD Million) TABLE 67. Israel pharmacovigilance market, by service provider, 2013 - 2024 (USD Million) Charts & Figures FIG 1. Industry segmentation FIG 2. Global pharmacovigilance market size, 2013 - 2024 (USD Million) FIG 3. Growth potential analysis, by clinical trial phase FIG 4. Growth potential analysis, by service provider FIG 5. Types of pharmacovigilance outsourcing vendors FIG 6. Porter's analysis FIG 7. Company market share analysis, 2017 FIG 8. Strategy dashboard FIG 9. PESTEL analysis

Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Market Insights, Inc.

New Pharmaceuticals and Healthcare Reports

Publisher: Global Market Insights, Inc. 162 Pages